Login to Your Account



BEYOND CD19 AND SOLID TUMORS?

No hard 'cell': CAR drives $134M series B for Juno as immunotherapy gains ground

By Randy Osborne
Staff Writer

Wednesday, August 6, 2014
Juno Therapeutics Inc.'s origins in three of the country's top oncology centers apparently has done plenty to help financing options for the Seattle-based firm, which added $134 million in series B cash to boost its chimeric antigen receptor (CAR) and T-cell receptor (TCR) pipeline. In less than 12 months, the Seattle-based company has raised more than $300 million.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription